probucol probucol probucol, sold under the trade name lorelco among others, is an anti-hyperlipidemic drug initially developed for the treatment of coronary artery disease. clinical development was discontinued after it was found that the drug may have the undesired effect of lowering hdl in patients with a previous history of heart disease. it may also cause qt interval prolongation. probucolclinical datatrade nameslorelcoother names2,6-di-tert-butyl-4-(sulfanyl)phenolahfs/drugs.commicromedex detailed consumer informationmedlineplusa611037atc codec10ax02 (who) identifiers iupac name 4,4'-bis(2,6-di-tert-butylphenol) cas number23288-49-5 ypubchem cid4912iuphar/bps7277drugbankdb01599 ychemspider4743 yuniip3cth044xjkeggd00476 ychebichebi:8427 nchemblchembl608 ycomptox dashboard (epa)dtxsid2045440 echa infocard100.041.404 chemical and physical dataformulac31h48o2s2molar mass516.84 g·mol−13d model (jsmol)interactive image smiles s(c1cc(c(o)c(c1)c(c)(c)c)c(c)(c)c)c(sc2cc(c(o)c(c2)c(c)(c)c)c(c)(c)c)(c)c inchi inchi=1s/c31h48o2s2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33h,1-14h3 ykey:fypmfjgvhohgll-uhfffaoysa-n y ny (what is this?) (verify) probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity. mechanism of action probucol lowers the level of cholesterol in the bloodstream by increasing the rate of ldl catabolism. additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption. probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in ldls; this slows the formation of foam cells, which form atherosclerotic plaques. after promising test results in mouse models, probucol is under study at weston brain institute of mcgill university as a possible aid in delaying the onset of alzheimer's disease. probucol has also been shown to inhibit abca1-dependent cholesterol transport, which may contribute to its known effect of lowering hdl.